Abstract
The ongoing SARS-CoV-2 (Covid-19) pandemic has ushered an unforeseen level of global health and economic burden. As a respiratory infection, Covid-19 is known to have a dominant airborne transmission modality, wherein fluid flow plays a central role. Quantification of complex non-intuitive dynamics and transport of pathogen laden respiratory particles in indoor flows has been of specific interest. Here we present a Lagrangian computational approach towards quantification of human-to-human exposure quantifiers, and identification of pathways by which flow organizes transmission. We develop a Lagrangian viral exposure index in a parametric form, accounting for key parameters such as building and layout, ventilation, occupancy, biological variables. We also employ a Lagrangian computation of the Finite Time Lyapunov Exponent field to identify hidden patterns of transport. A systematic parametric study comprising a set of 120 simulations, yielding a total of 1,320 different exposure index computations are presented. Results from these simulations enable: (a) understanding the otherwise hidden ways in which air flow organizes the long-range transport of such particles; and (b) translating the micro-particle transport data into a quantifier for understanding infection exposure risks.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work utilized resources from the University of Colorado Boulder Research Computing Group, which is supported by the National Science Foundation (awards ACI-1532235 and ACI-1532236), the University of Colorado Boulder, and Colorado State University. The Authors also acknowledge the availability of an academic license from SimScale to complete this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not applicable for this study
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All associated data have been presented in the manuscript.
